Corrigendum to “The global threat of antimicrobial resistance: science for intervention” [New Microbes New Infect 6 (2015): 22–29]

• I. Roca,
• M. Akova,
• F. Baquero,
• J. Carlet,
• M. Cavaleri,
• S. Coenen,
• J. Cohen,
• D. Findlay,
• I. Gyssens,
• O.E. Heuer,
• G. Kahlmeter,
• H. Kruse,
• R. Laxminarayan,
• E. Liébana,
• L. López-Cerero,
• A. MacGowan,
• M. Martins,
• J. Rodríguez-Baño,
• J.-M. Rolain,
• C. Segovia,
• B. Sigauque,
• E. Tacconelli,
• E. Wellington,
• J. Vila

Affiliations

I. Roca

ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic—Universitat de Barcelona, Barcelona, Spain

M. Akova

Department of Medicine, Section of Infectious Diseases, Hacettepe University School of Medicine, Ankara, Turkey

F. Baquero

Department of Microbiology at the Ramón y Cajal University Hospital, Ramón y Cajal Institute for Health Research (IRYCIS), Division for Research in Microbial Biology and Evolution, CIBERESP, Madrid, Spain

J. Carlet

Fondation Hôpital St, Joseph, Paris, France and World Alliance Against Antibiotic Resistance (WAAAR), Creteil, France

M. Cavaleri

European Medicines Agency (EMA), London, UK

S. Coenen

Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium

J. Cohen

Brighton and Sussex Medical School, Brighton, UK

D. Findlay

Global Commercial Lead, GlaxoSmithKline (GSK), London, UK

I. Gyssens

Department of Medicine, Radboud University Medical Center and Department of Medical Microbiology and Infectious Diseases, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands

O.E. Heuer

European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden

G. Kahlmeter

Clinical Microbiology, Central Hospital, Växjö, Sweden

H. Kruse

WHO Regional Office for Europe, UN City, Marmorvej, Copenhagen, Denmark

R. Laxminarayan

Center for Disease Dynamics, Economics and Policy, Washington, DC, USA

E. Liébana

Scientific Unit on Biological Hazards, European Food Safety Authority (EFSA), Parma, Italy

L. López-Cerero

Unidad Clínica de Enfermedades Infecciosas y Microbiología, Hospital Universitario Virgen Macarena, Seville, Spain

A. MacGowan

Department of Medical Microbiology, Southmead Hospital, Bristol, UK

M. Martins

School of Public Health, Physiotherapy and Population Science, UCD Centre for Food and Safety, Molecular Innovation and Drug Discovery, University College Dublin, Dublin, Ireland

J. Rodríguez-Baño

Unidad Clínica de Enfermedades Infecciosas y Microbiología, Hospital Universitario Virgen Macarena, and Departamento de Medicina, Universidad de Sevilla, Seville, Spain

J.-M. Rolain

Aix-Marseille Université, Unité de Recherche en Maladies Infectieuses et Tropicales Emergentes (URMITE), Inserm, IHU Méditerranée Infection, Faculté de Médecine et de Pharmacie, and APHM, CHU Timone, Pôle Infectieux, Marseille, France

C. Segovia

Instituto de Salud Carlos III, ISCIII, Madrid, Spain

B. Sigauque

Centro de Investigação em Saúde da Manhiça and Instituto Nacional de Saúde/Ministério de Saúde, Maputo, Mozambique

E. Tacconelli

Division of Infectious Diseases, Department of Internal Medicine I, Tübingen University Hospital, Tübingen, Germany

E. Wellington

School of Life Sciences, University of Warwick, Coventry, UK

J. Vila

ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic—Universitat de Barcelona, Barcelona, Spain